Navigation Links
Targeting des B-Zell-Rezeptors in aggressiven B-Zell-Lymphomen
Date:6/14/2013

s wir erstmals nachweisen können, dass Tumoren, die diese spezifischen Abnormalitäten bei der BCR-Signalübertragung aufweisen, gegenüber Ibrutinib am anfälligsten sind. Die Proof-of-Principle-Studie wird Forschern bei der Bestimmung von Patienten helfen, die mit der größten Wahrscheinlichkeit von diesem Arzneimittel profitieren werden.

Präsentator: Wyndham H. Wilson

Zugehörigkeit: National Cancer Institute, USA

Thema: "THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS" (Auszug Nummer S1180)

Informationen zum EHA-Jahreskongress

Die Hämatologie ist ein Spezialgebiet, das sich mit allen Aspekten rund um das Thema Blut befasst: seinem Ursprung im Knochenmark, mit Blutkrankheiten und mit deren Behandlung. Im Rahmen des Kongresses werden die neuesten Forschungs- und Entwicklungsdaten präsentiert werden. Die behandelten Themen reichen von der Physiologie und Entwicklung von Stammzellen sowie der Diagnose und Behandlung von Leukämie, Lymphomen und Myelomen über Erkrankungen der roten und weißen Blutkörperchen und der Blutplättchen bis zu Thrombose und Blutungsstörungen.


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
4. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
5. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
6. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
7. Allazo Health CEO at Wharton Health Care Conference Shows how Predictive Analytics and Individualized Intervention Targeting Promote Medication Adherence.
8. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
9. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
10. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
11. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... 14, 2011 Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a ... (IVD) cancer tests, today announced financial results for its ... for the third quarter ended September 30, 2011 were ... September 30, 2010.  For the nine months ended September ...
... Corporation (NASDAQ: LMNX ) today announced ... at the Defense Threat Reduction Agency,s (DTRA) 2011 ... Conference, which takes place November 14-16, 2011 in ... During the conference, Dr. Altman will present ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 2Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 3
(Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... international scientists have developed a new method to study ... , The Wildlife Conservation Society (WCS)-led research, published today ... describes the use of fecal samples from wild great ... to the virus. This represents a new tool for ... the way Ebola virus is studied and improve our ...
(Date:9/18/2014)... 2014) The National Institutes of Health (NIH) recently ... $1.3 million grant to the Los Angeles Biomedical Research ... development of a vaccine to protect patients from the ... aureus (MRSA). , The National Institute of ... the grant to LA BioMed infectious disease specialists John ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... joined hands today to boost efforts by governments in ... ,Headed by C Rangarajan, Chairman of the ... independent commission on AIDS in Asia and the Pacific ... of AIDS in the region and its medium- and ...
... an important ingredient in magic mushrooms is capable of ... addictions. ,Researchers at Johns Hopkins University ... element in mushrooms is capable of instilling a deep ... for those patients who have a huge psychological baggage ...
... about 1,500 medical professionals are available throughout the country ... in India // , President of Madras ENT Rearch ... ,Most of these professionals were concentrated in major ... said at a press conference prior to the inauguration ...
... reported in the United Kingdom, asthmatics will witness almost ... months of completely// staying off cigarettes. ... lung function seen after smoking cessation was clinically significant. ... the harmful effects of smoking on the airways in ...
... to invest more money in mental health, to bridge the ... , Although the new national mental health plan provided a ... short of the escalating expenditure, said John Mendoza, the chief ... ,Mr. Mendoza said that only 40 per cent ...
... the University of Vermont say that drinking cherry juice may ... number of antioxidant// and anti-inflammatory compounds that can deal with ... The British Journal of Sports Medicine, researchers said that men ... levels of inflammatory markers in their blood. The study examined ...
Cached Medicine News:
Electric high speed system....
... High Performance Instrument System was ... for increased power of the ... It provides 60% more torque ... easily handle the most demanding ...
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
... Platinum is a compact and quiet, ... at 120 psi/8 bar, it provides ... size with noticeable noise reduction. A ... with an enhanced ergonomic handpiece to ...
Medicine Products: